Better Cathie Wood Stock: Moderna vs. Intellia
Cathie Wood's latest stocks shopping spree included several healthcare innovators -- and she picked them up for a bargain. Wood isn't intimidated by shares that have wallowed in the doldrums because she favors long-term investing. The idea is to buy promising companies for a good price and hold onto the shares for a number of years -- giving those companies time to bring products to market and grow earnings. And that should boost share performance over time.
This week, Wood has been adding to her positions in biotech companies Moderna (NASDAQ: MRNA) and Intellia Therapeutics (NASDAQ: NTLA). Moderna, the maker of a leading coronavirus vaccine, is an expert in mRNA medicine, while Intellia is bringing exciting gene editing candidates through the pipeline. Their shares have dropped 28% and 31%, respectively, over the past year, but Wood clearly sees the long-term potential of these players.
Considering this famous investor's expertise in identifying fantastic long-term opportunities, you may want to follow her into these stocks. But if you could only buy one, which makes the better buy right now?
Source Fool.com
Intellia Therapeutics Inc Aktie
Die Intellia Therapeutics Inc Aktie erhält starke Unterstützung mit mehreren Buy- und keiner Sell-Einschätzung.
Das Kursziel von 60 €, festgelegt von der Community für Intellia Therapeutics Inc, zeigt ein Potenzial von 176.5%, was einer Verdopplung des aktuellen Kurses entspricht.
